QUOTE AND NEWS
Forbes  Aug 11  Comment 
Looking back to 2 days ago, BioMarin Pharmaceutical Inc. (NASD: BMRN) priced a 7,500,000 share secondary stock offering at $96.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment...
Motley Fool  Aug 10  Comment 
The biotech's drugs are on pace to surpass $1 billion cumulatively, but it has pipeline drugs that could each produce that much on their own.
Motley Fool  Aug 6  Comment 
A rare-disease application and a hemophilia program update helped, but the main reason BioMarin had such a great month is much simpler.
SeekingAlpha  Aug 5  Comment 
Forbes  Jul 28  Comment 
BioMarin became one of the world's most valuable biotechs by jettisoning costly distractions and focusing on one thing: treating some of the rarest diseases on the planet.
FierceBiotech  Jul 27  Comment 
BioMarin up on positive gene therapy data in hemophilia A slawrence Wed, 07/27/2016 - 16:43
Forbes  Jul 18  Comment 
Investors in BioMarin Pharmaceutical Inc. (NASD: BMRN) saw new options begin trading today, for the September 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BMRN options chain for the new September...




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki